Pcas SA
PAR:PCA
Intrinsic Value
PCAS SA engages in the development, manufacture, and sale of chemicals. [ Read More ]
The intrinsic value of one PCA stock under the Base Case scenario is 14.64 EUR. Compared to the current market price of 8 EUR, Pcas SA is Undervalued by 45%.
Valuation Backtest
Pcas SA
Run backtest to discover the historical profit from buying and selling PCA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pcas SA
Current Assets | 150.1m |
Cash & Short-Term Investments | 266k |
Receivables | 74.6m |
Other Current Assets | 75.3m |
Non-Current Assets | 151.7m |
Long-Term Investments | 117k |
PP&E | 148.7m |
Intangibles | 2.9m |
Other Non-Current Assets | 41k |
Current Liabilities | 217.1m |
Accounts Payable | 33.6m |
Accrued Liabilities | 23.4m |
Other Current Liabilities | 160m |
Non-Current Liabilities | 77.6m |
Long-Term Debt | 67.9m |
Other Non-Current Liabilities | 9.7m |
Earnings Waterfall
Pcas SA
Revenue
|
230m
EUR
|
Cost of Revenue
|
-145.9m
EUR
|
Gross Profit
|
84.1m
EUR
|
Operating Expenses
|
-110.5m
EUR
|
Operating Income
|
-26.4m
EUR
|
Other Expenses
|
35.2m
EUR
|
Net Income
|
8.8m
EUR
|
Free Cash Flow Analysis
Pcas SA
PCA Profitability Score
Profitability Due Diligence
Pcas SA's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Pcas SA's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
PCA Solvency Score
Solvency Due Diligence
Pcas SA's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Score
Pcas SA's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PCA Price Targets Summary
Pcas SA
According to Wall Street analysts, the average 1-year price target for PCA is 14.5 EUR .
Shareholder Return
PCA Price
Pcas SA
Average Annual Return | 19.33% |
Standard Deviation of Annual Returns | 55.35% |
Max Drawdown | -60% |
Market Capitalization | 109.9m EUR |
Shares Outstanding | 13 741 673 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
PCAS SA engages in the development, manufacture, and sale of chemicals. The company is headquartered in Ecully, Auvergne-Rhone-Alpes. The company operates through nine production sites and two main business units, Pharma Synthesis and Fine & Specialty Chemicals. Pharma Synthesis unit specializes in active pharmaceutical ingredients (API), intermediates and building blocks, and early phase services, among others. Fine & Specialty Chemicals unit focuses on custom manufacturing and proprietary products, such as fragrance, flavor ingredients, imaging and microelectronics chemicals. The firm operates several subsidiaries, including Saint-Jean Photochimie, Societe Bearnaise de Synthese, Expansia, PCAS BioMatrix Inc, based in Canada, and PCAS Finland Oy, based in Finland, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one PCA stock under the Base Case scenario is 14.64 EUR.
Compared to the current market price of 8 EUR, Pcas SA is Undervalued by 45%.